






PHARMACEUTICAL 2021

Inmed Pharmaceuticals Inc Rank 260 of 394

The relative strengths and weaknesses of Inmed Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Inmed Pharmaceuticals Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 63% points. The greatest weakness of Inmed Pharmaceuticals Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 81% points.

The company's Economic Capital Ratio, given in the ranking table, is 210%, being 46% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	6,312
Cost of Goods Sold	0
Intangible Assets	1,087
Liabilities, Current	1,676
Liabilities, Non-Current	248
Other Assets	0
Other Compr. Net Income	-420
Other Expenses	112
Other Liabilities	0
Other Net Income	212
Other Revenues	0
Property and Equipment	403
Research and Development	5,811
Selling, General and Administrative Expense	3,227

Output Variable	Value in 1000 USD
Assets	7,803
Liabilities	1,924
Expenses	9,151
Revenues	0
Stockholders Equity	5,878
Net Income	-8,939
Comprehensive Net Income	-9,149
BaseVar	9,755
ECR before LimitedLiability	75%
Economic Capital Ratio	210%